Editas Medicine, Inc. (EDIT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
EDIT currently has 97.9M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 19.73% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 26, 2026 |
8-K filing: Editas Medicine, Inc. entered into an underwriting agreement for a public offering of 55,555,556 shares of common stock and accompanying common stock warrants at a combined price of $2.25 per share. ($125.0M proceeds) |
98M | 0 |
| May 26, 2026 |
8-K filing: Editas Medicine, Inc. terminated the current prospectus supplement for its at-the-market offering program after selling an aggregate of 14,327,365 shares for $43.9 million. ($43.9M proceeds) |
98M | 0 |
| May 05, 2026 |
10-Q filing | 97.9M shares outstanding |
98M | 0 |
| Mar 09, 2026 |
10-K filing | 88.7M shares outstanding |
89M | 0 |
| Nov 10, 2025 |
10-Q filing | 90.1M shares outstanding |
90M | 0 |
| Aug 12, 2025 |
10-Q filing | 84.4M shares outstanding |
84M | 0 |
| May 12, 2025 |
10-Q filing | 83.1M shares outstanding |
83M | 0 |
| Mar 05, 2025 |
POS AM filing: The company is filing a POS AM to offer and sell securities from time to time in one or more offerings of up to $350,000,000 in aggregate offering price including Common Stock, Preferred Stock, Debt Securities, Depositary Shares, Subscription Rights, Purchase Contracts, Warrants, and Units, and is also offering shares of common stock having an aggregate offering price of up to $150,000,000. |
83M | 0 |
| Mar 05, 2025 |
10-K filing | 82.3M shares outstanding |
82M | 150K |
| Nov 04, 2024 |
10-Q filing | 82.5M shares outstanding |
82M | 0 |
| Aug 07, 2024 |
10-Q filing | 82.3M shares outstanding |
82M | 0 |
| May 08, 2024 |
10-Q filing | 81.9M shares outstanding |
82M | 0 |
| Feb 28, 2024 |
10-K filing | 76.0M shares outstanding |
76M | 0 |
| Nov 03, 2023 |
10-Q filing | 81.6M shares outstanding |
82M | 0 |
| Aug 02, 2023 |
10-Q filing | 81.6M shares outstanding |
82M | 0 |
| Jun 15, 2023 |
8-K filing: Editas Medicine, Inc. entered into an underwriting agreement for a public offering of 12,500,000 shares of common stock at $10.00 per share, with an option for the underwriters to purchase an additional 1,875,000 shares. ($134.83M proceeds) |
69M | 0 |
| May 05, 2023 |
10-Q filing | 68.9M shares outstanding |
69M | 0 |
| Feb 22, 2023 |
10-K filing | 68.7M shares outstanding |
69M | 0 |
| Nov 02, 2022 |
10-Q filing | 68.7M shares outstanding |
69M | 0 |
| Aug 03, 2022 |
10-Q filing | 68.6M shares outstanding |
69M | 0 |
| May 04, 2022 |
10-Q filing | 68.5M shares outstanding |
68M | 0 |
| Feb 24, 2022 |
10-K filing | 67.6M shares outstanding |
68M | 0 |
| Nov 09, 2021 |
10-Q filing | 68.2M shares outstanding |
68M | 0 |
| Aug 05, 2021 |
10-Q filing | 67.9M shares outstanding |
68M | 0 |
| May 06, 2021 |
10-Q filing | 66.0M shares outstanding |
66M | 0 |
| Feb 26, 2021 |
10-K filing | 67.4M shares outstanding |
67M | 0 |
| Jan 21, 2021 |
8-K filing: Editas Medicine, Inc. announced an underwritten public offering of 3,500,000 shares of common stock at a price of $66.00 per share, with an option for the Underwriters to purchase up to an additional 525,000 shares. ($216.9M proceeds) |
62M | 0 |
| Nov 06, 2020 |
10-Q filing | 62.1M shares outstanding |
62M | 0 |
| Aug 07, 2020 |
10-Q filing | 62.3M shares outstanding |
62M | 0 |
| Jun 25, 2020 |
8-K filing: Editas Medicine, Inc. announced an underwritten public offering of 6,000,000 shares of common stock at $31.25 per share, with an option for the underwriter to purchase up to an additional 900,000 shares. ($177.0M proceeds) |
55M | 0 |
| May 08, 2020 |
10-Q filing | 55.0M shares outstanding |
55M | 0 |
| Feb 26, 2020 |
10-K filing | 54.9M shares outstanding |
55M | 0 |